Thursday , 25 April 2024

Design and Characterization of Chronotherapeutic Drug Delivery System of Dexibuprofen for the Treatment of Arthritis

Kishor*1, Bindu Madhavi2, K. Someshwar2
1Department of Pharmceutics, St. Pauls College of Pharmacy, Hyderabad, Telangana, India
2Manager, Formulation R&D, KP Labs (A Division of KDPL), Kothapet, Hyderabad Telangana, India

A B S T R A C T
In the present research work, chronotherapeutic drug delivery of Dexibuprofen was carried out. Chronotherapeutics refers to a treatment method in which in-vivo drug availability is timed to match rhythms of disease, in order to maximize the health benefits and minimize the adverse effects. Literature review was carried out regarding chronotherapeutic tablets, from that Dexibuprofen was selected as model drug and various grades of HPMC and Eudragit were selected as polymers. Analytical profile of drug molecule was established in 0.1 N HCL, 6.8 pH phosphate buffer and 7.4 pH phosphate buffer and standard calibration curve was plotted by taking different concentrations. The drug and excipient compatibility studies were carried out by using FTIR spectroscopy. From the studies it was evident taht the drug and excipients are compatible with each other. Core tablets were formulated with varying concentrations of HPMC K100, HPMC E15M and Ethyl cellulose. The formulated core tablets were evaluated for various evaluation parameters. The optimized formulation was being coated with the different coating formulations Eudragit L 100 and Eudragit S 100 (1:1) in combination (7.5 %), in the form of compressed coating polymers. The compressed coated were evaluated for various evaluation parameters. Analysis of drug release mechanism showed that the drug release from the formulations followed non-Fickian diffusion and the best fit model was found to be Korsmeyer-Peppas and Zero order. Based on the results of evaluation tests formulation coded CF 10 was concluded as best formulation.
Keywords: Dexibuprofen, HPMC, Ethyl cellulose, Eudragit L 100 & Eurdagit s 100, Cumulative % of drug release, Chronotherapeutic drug delivery.

Scroll To Top